BR112018014590A2 - formulações/composições compreendendo um inibidor de btk - Google Patents
formulações/composições compreendendo um inibidor de btkInfo
- Publication number
- BR112018014590A2 BR112018014590A2 BR112018014590A BR112018014590A BR112018014590A2 BR 112018014590 A2 BR112018014590 A2 BR 112018014590A2 BR 112018014590 A BR112018014590 A BR 112018014590A BR 112018014590 A BR112018014590 A BR 112018014590A BR 112018014590 A2 BR112018014590 A2 BR 112018014590A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- compositions
- btk inhibitor
- ibrutinib
- formu
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 238000009472 formulation Methods 0.000 title abstract 4
- 229940124291 BTK inhibitor Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001507 ibrutinib Drugs 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
a presente invenção refere-se a formulações/composições compreendendo um inibidor de btk, particularmente ibrutinibe (fórmu-a i) bem como processos para preparação de tais formulações/composições e métodos de tratamento de uma doença ou condição que compreendem o uso de tais formulações/composições.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621001986 | 2016-01-19 | ||
PCT/EP2017/050962 WO2017125423A1 (en) | 2016-01-19 | 2017-01-18 | Formulations/compositions comprising a btk inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018014590A2 true BR112018014590A2 (pt) | 2018-12-11 |
Family
ID=57851067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018014590A BR112018014590A2 (pt) | 2016-01-19 | 2017-01-18 | formulações/composições compreendendo um inibidor de btk |
Country Status (15)
Country | Link |
---|---|
US (2) | US20190282577A1 (pt) |
EP (1) | EP3405177A1 (pt) |
JP (3) | JP7109365B2 (pt) |
KR (1) | KR20180101521A (pt) |
CN (1) | CN108472259A (pt) |
AR (1) | AR107391A1 (pt) |
AU (2) | AU2017208472B2 (pt) |
BR (1) | BR112018014590A2 (pt) |
CA (1) | CA3008338A1 (pt) |
EA (1) | EA201891440A1 (pt) |
HK (2) | HK1259440A1 (pt) |
MA (1) | MA43649A (pt) |
MX (2) | MX2018008771A (pt) |
TW (1) | TWI803454B (pt) |
WO (1) | WO2017125423A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
AU2016226279B2 (en) | 2015-03-03 | 2021-11-11 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
WO2019142207A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
BR112020024481A2 (pt) | 2018-06-15 | 2021-03-02 | Janssen Pharmaceutica Nv | formulações/composições compreendendo ibrutinib |
US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
RU2120798C1 (ru) | 1991-11-22 | 1998-10-27 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Твердая фармацевтическая композиция для перорального введения |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
ATE223704T1 (de) | 1992-10-16 | 2002-09-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
WO2005024043A2 (en) | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
ES2585902T3 (es) | 2006-09-22 | 2016-10-10 | Pharmacyclics Llc | Inhibidores de tirosina cinasa de Bruton |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CA3218491A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
WO2016022942A1 (en) * | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
AU2016226279B2 (en) * | 2015-03-03 | 2021-11-11 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor |
-
2017
- 2017-01-18 MX MX2018008771A patent/MX2018008771A/es unknown
- 2017-01-18 EA EA201891440A patent/EA201891440A1/ru unknown
- 2017-01-18 BR BR112018014590A patent/BR112018014590A2/pt not_active Application Discontinuation
- 2017-01-18 US US16/071,448 patent/US20190282577A1/en not_active Abandoned
- 2017-01-18 KR KR1020187023222A patent/KR20180101521A/ko not_active Application Discontinuation
- 2017-01-18 CN CN201780006752.0A patent/CN108472259A/zh active Pending
- 2017-01-18 WO PCT/EP2017/050962 patent/WO2017125423A1/en active Application Filing
- 2017-01-18 CA CA3008338A patent/CA3008338A1/en active Pending
- 2017-01-18 EP EP17700820.8A patent/EP3405177A1/en active Pending
- 2017-01-18 JP JP2018537505A patent/JP7109365B2/ja active Active
- 2017-01-18 AU AU2017208472A patent/AU2017208472B2/en active Active
- 2017-01-18 MA MA043649A patent/MA43649A/fr unknown
- 2017-01-19 AR ARP170100141A patent/AR107391A1/es unknown
- 2017-01-19 TW TW106101783A patent/TWI803454B/zh active
-
2018
- 2018-07-17 MX MX2022006768A patent/MX2022006768A/es unknown
-
2019
- 2019-02-01 HK HK19101844.5A patent/HK1259440A1/zh unknown
- 2019-02-01 HK HK19101838.3A patent/HK1259434A1/zh unknown
-
2022
- 2022-04-07 JP JP2022063871A patent/JP2022105009A/ja active Pending
- 2022-05-04 US US17/736,305 patent/US20220339157A1/en active Pending
- 2022-11-25 AU AU2022275514A patent/AU2022275514A1/en active Pending
-
2023
- 2023-10-25 JP JP2023183050A patent/JP2024023184A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI803454B (zh) | 2023-06-01 |
AU2017208472A1 (en) | 2018-07-05 |
MA43649A (fr) | 2018-11-28 |
AR107391A1 (es) | 2018-04-25 |
EA201891440A1 (ru) | 2018-12-28 |
AU2022275514A1 (en) | 2023-01-05 |
HK1259440A1 (zh) | 2019-11-29 |
MX2022006768A (es) | 2022-06-17 |
HK1259434A1 (zh) | 2019-11-29 |
MX2018008771A (es) | 2018-11-09 |
AU2017208472B2 (en) | 2022-09-01 |
JP2022105009A (ja) | 2022-07-12 |
TW201731513A (zh) | 2017-09-16 |
CN108472259A (zh) | 2018-08-31 |
JP7109365B2 (ja) | 2022-07-29 |
US20220339157A1 (en) | 2022-10-27 |
EP3405177A1 (en) | 2018-11-28 |
KR20180101521A (ko) | 2018-09-12 |
JP2019506387A (ja) | 2019-03-07 |
WO2017125423A1 (en) | 2017-07-27 |
JP2024023184A (ja) | 2024-02-21 |
CA3008338A1 (en) | 2017-07-27 |
US20190282577A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017011851A2 (es) | Compuestos novedosos | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
CO2021005987A2 (es) | Compuestos de anillo fusionado | |
BR112019004100A2 (pt) | compostos de biarila úteis como imunomoduladores | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
BR112017009648A2 (pt) | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. | |
BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
BR112016024096A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
CR20160557A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 | |
BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
ECSP17010482A (es) | Novedosas pirimidinas 2,5-sustituidas | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |